BackgroundThe Coronavirus diseases (COVID-19) pandemic is not abating and there is no approved treatment yet. The development of vaccines is hoped to help in addressing this disease outbreak. However, in the face of anti-vaccines uprise, it is important to understand the factors that may influence the uptake of COVID-19 vaccines as this will influence how successful the fight against COVID-19 will be in the long term.MethodsA cross-sectional study among 776 adult Nigerians (age ≥18 years) was conducted in the 36 States of Nigeria and the Capital City with online questionnaire. The questionnaire consisted of 5 sections: socio-demographic characteristics of respondents, respondent’s knowledge of COVID-19, respondents risk perception of COVID-19, vaccination history of respondents, and willingness to receive COVID-19 vaccine. Descriptive analysis of variables was done and multivariate analysis using logistic regression was carried out to determine the predictors of uptake of a potential COVID-19 vaccine. The level of significance was predetermined at a p-value < 0.05. Data analysis was done with SPSS version 21.ResultsMost of the respondents were male (58.1%). Most participants were willing to take a potential COVID-19 vaccine (58.2%), while 19.2% would not take it with 22.6% indecisive. 53.5% would prefer a single dose COVID-19 vaccine. For vaccine uptake, being male (p= 0.002) and the perception that “vaccines are good” (p< 0.001) were the positive predictor of uptake of a potential COVID-19 vaccine.ConclusionMost Nigerians were willing to take a potential COVID-19 vaccine with the male gender and perception that “vaccines are good” being positive predictors. There is a need for public enlightenment aim at encouraging those that are indecisive or averse to receiving COVID-19 vaccines.
Stimulation and generation of T and B cell mediated long-term immune response is essential for the curbing of a deadly virus such as SAR-CoV-2. Immunoinformatics approach in vaccine design takes advantage of antigenic and non-allergenic epitopes present on the spike glycoprotein of SARS-CoV-2 to elicit immune responses. T cells and B cells epitopes were predicted, and the selected residues were subjected to allergenicity, antigenicity and toxicity screening which were linked by appropriate linkers to form a multi-epitope subunit vaccine. The physiochemical properties of the vaccine construct was analyzed and the molecular weight, molecular formula, theoretical isoelectric point value, half-life, solubility score, instability index, aliphatic index and GRAVY were predicted. The vaccine structure was constructed, refined, validated, and disulfide engineered to get the best model. Molecular binding simulation and molecular dynamics simulation were carried out to predict the stability and binding affinity of the vaccine construct with TLRs. Codon acclimatization and in silico cloning were performed to confirm the vaccine expression and potency. Results obtained indicated that this novel vaccine candidate is non-toxic, capable of initiating the immunogenic response and will not induce an allergic reaction. The highest binding energy was observed in TLR 4 (-1398.1) and the least is TLR 2 (-1479. 6). The steady rise in Th (helper) cell population with memory development was noticed and IFN-g was provoked after simulation. At this point, the vaccine candidate awaits animal trial to validate its efficacy and safety for use in the prevention of the novel COVID-19 infections.
Africa, challenges, COVID-19, implications, laboratory diagnosisThe COVID-19 infection has been a matter of urgency to tackle around the world today, there exist 200 countries around the world and 54 countries in Africa that the COVID-19 infection cases have been confirmed. This situation prompted us to look into the challenges African laboratories are facing in the diagnosis of novel COVID-19 infection. A limited supply of essential laboratory equipment and test kits are some of the challenges faced in combatting the novel virus in Africa. Also, there is inadequate skilled personnel, which might pose a significant danger in case there is a surge in COVID-19 infection cases. The choice of diagnostic method in Africa is limited as there are only two available diagnostic methods being used out of the six methods used globally, thereby reducing the opportunity of supplementary diagnosis, which will further lead to inappropriate diagnosis and affect the accuracy of diagnostic reports. Furthermore, challenges like inadequate power supply, the method used in sample collection, storage and transportation of specimens are also significant as they also pose their respective implication. From the observations, there is an urgent need for more investment into the laboratories for proper, timely, and accurate diagnosis of COVID-19.
The approval of vaccines for emergency use signifies a great milestone to end the COVID-19 pandemic. However, less than 2% of the global vaccines have been administered in Africa, putting the continent in a precarious situation in the eventuality of another wave that may consume its health system. There is still an enormous task in Africa in the face of vaccine nationalism. In most countries, vaccine acquisition and deployment have been suboptimal. Leaving out Africa in the race to achieve global herd immunity may be catastrophic. Stakeholders must continue engagement to ensure a successful deployment of the vaccines on the continent. There is a need to build capacity in Africa for rapid vaccine development and deployment in the long term.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.